BC Innovations | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
BC Week In Review | May 30, 2016
Company News

XenoPort, Arbor Pharmaceuticals deal

Specialty pharma Arbor will acquire XenoPort for $7.03 per share in a cash deal the companies say values XenoPort at $467 million. The price is a 60% premium to XenoPort’s close of $4.40 on May...
BC Extra | May 24, 2016
Company News

Arbor acquiring XenoPort

Specialty pharma Arbor Pharmaceuticals Inc. (Atlanta, Ga.) is acquiring XenoPort Inc. (NASDAQ:XNPT) for $7.03 per share, or about $467 million. The deal will give Arbor rights to Horizant gabapentin enacarbil , which is approved in the...
BC Extra | Mar 29, 2016
Company News

Dr. Reddy's, XenoPort strike deal for psoriasis therapy

XenoPort Inc. (NASDAQ:XNPT) granted Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) exclusive, U.S. rights to develop and commercialize XP23829 , which has completed a Phase II trial to treat moderate to severe chronic plaque-type psoriasis. The compound is...
BioCentury | Jan 4, 2016
Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
BC Week In Review | Oct 12, 2015
Clinical News

XP23829: Development discontinued

XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported data from a Phase II trial of XP23829 to...
BC Week In Review | Oct 12, 2015
Company News

XenoPort neurology, autoimmune news

XenoPort will reduce headcount by 25 (14%) to about 155 and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. Cuts include positions related to the XP23829 program. Additionally,...
BC Extra | Oct 2, 2015
Company News

XenoPort gains on restructuring plans

XenoPort Inc. (NASDAQ:XNPT) gained $0.84 (24%) to $4.32 after the company said it is replacing its CEO and plans to partner XP23829 and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil . EVP and...
BC Week In Review | Jul 20, 2015
Clinical News

Horizant gabapentin enacarbil: Phase II started

XenoPort said NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) began the double-blind, placebo-controlled, U.S. Phase II NCIG-006 trial to evaluate 600 mg oral Horizant twice daily for 26 weeks in about 350 patients....
BC Innovations | Oct 16, 2014
Translation in Brief

Translational tidbits

Big drive for big data In the last month, the NIH has pledged almost $100 million for big data programs aimed at making information usable and accessible to the wider research community and to create...
Items per page:
1 - 10 of 219